ATI Inc/ US01741R1023 /

5/24/2024 10:10:00 PM	Chg. +1.28	Volume	Bid2:00:00 AM	Ask2:00:00 AM	Market Capitalization	Dividend Y.	P/E Ratio
60.53USD	+2.16%	1.19 mill. Turnover: 34.87 mill.	47.32Bid Size: 100	62.22Ask Size: 100	7.53 bill.USD	-	18.86

GlobeNewswire 5/23 Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...

GlobeNewswire 5/21 Acoustic Technology, Inc. (ATI Systems) Revolutionizes Emergency Communication with Unique Advanced ...

GlobeNewswire 5/13 Astrotech Reports Third Quarter of Fiscal Year 2024 Financial Results

GlobeNewswire 5/9 TTM Technologies, Inc. Appoints Wajid Ali to Board of Directors

GlobeNewswire 5/7 Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire 3/27 William & Mary Campus Mass Notification Drill Using ATI Systems’ Mass Notiﬁcation Solution

GlobeNewswire 3/12 Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks

GlobeNewswire 2/13 Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

GlobeNewswire 2/6 Seoul Robotics to Pursue Initial Public Offering with Samsung Securities as it Expands OEM Partnersh...

GlobeNewswire 1/25 Confluent Announces Significant Investment in ATI Nitinol Melt Expansion

GlobeNewswire 1/17 IBN Coverage Initiated for Astrotech Corp.

GlobeNewswire 1/16 Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review

GlobeNewswire 12/27/2023 Eco Bright Future, Inc. Announces Signing of "Letter-of-Intent" With United Heritage, Sociedad Anoni...

GlobeNewswire 12/12/2023 Astrotech Announces Exciting New Technology Application and Introduces New Subsidiary

GlobeNewswire 12/5/2023 American Trust Insurance Joins World Insurance Associates

GlobeNewswire 11/27/2023 ATI Systems Honored with 2023 ‘ASTORS’ Homeland Security Award

GlobeNewswire 11/13/2023 Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (AT...

GlobeNewswire 11/6/2023 Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

GlobeNewswire 10/27/2023 Strategic Advisory Board Elevates sureti’s Property Claims Resolution Capabilities

GlobeNewswire 10/25/2023 Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT...

GlobeNewswire 10/23/2023 ATI PHYSICAL THERAPY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...

GlobeNewswire 10/19/2023 Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV a...

GlobeNewswire 10/3/2023 Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic De...

GlobeNewswire 9/30/2023 ATI PHYSICAL THERAPY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...

GlobeNewswire 9/19/2023 ATI PHYSICAL THERAPY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...